KLK3 and Familial prostate cancer: In vivo evaluation of this inhibitor through intravenous injection at a dose of 33 mg/kg for two cycles of three consecutive days in human prostate cancer xeno-grafted mice led to significant reduction in KLK3 serum levels (free KLK3 levels by 35% and total KLK3 levels by 30%), however, had minimal effect on tumor growth [128].